Skip to main navigation Skip to search Skip to main content

PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC

  • Xiuchao Wang
  • , Xin Li
  • , Xunbin Wei
  • , Haiping Jiang
  • , Chungen Lan
  • , Shengyu Yang
  • , Han Wang
  • , Yanhui Yang
  • , Caijuan Tian
  • , Zanmei Xu
  • , Jiangyan Zhang
  • , Jihui Hao
  • , He Ren

Research output: Contribution to journal › Article › peer-review

121   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC'. Together they form a unique fingerprint.
Sort by

Keyphrases

Immunology and Microbiology